Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon canceer cell line

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1591-1597

  Toffoli, G ^a   Corona, G ^a   Gigante, M ^a   Boiocchi, M ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cell cycle; Pgp; Verapamil

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; VERAPAMIL;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; COLON CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0030217848     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00113-X     Document Type: Article

References (19)

1. 1. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 1993, 72, 3553-3563.
2. 2. Dalton WS. Drug resistance modulation in the laboratory and the clinic. Semin Oncol 1993, 20, 64-69.
3. 3. Lehnert M. Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues. Eur J Cancer 1993, 29A, 636-638.
4. 4. Cazin JL, Gosselin P, Cappelaere P, Robert J, Demaille A. Drug resistance in oncology: from concepts to applications. J Cancer Res Clin Oncol 1992, 119, 76-86.
5. 5. De Vita VT. The problem of resistance keynote address. In Mihich E, ed. Drug Resistance: Mechanisms and Reversal. Roma, John Libbey CIC, 1990, 7-27.
6. 6. Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res 1978, 38, 4722-4727.
7. 7. Gervasoni JE Jr, Fields SZ, Krishna S, et al. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res 1991, 51, 4955-4963.
8. 8. Schuurhuis GJ, van Heijningen THM, Cervantes A, et al. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993, 68, 898-908.
9. 9. Boiocchi M, Toffoli G. Mechanisms of multidrug resistance in human tumor cell lines and complete reversion of cellular resistance. Eur J Cancer 1992, 28A, 1099-1105.
10. 10. Lee FJF, Flannery DJ, Siemann DW. Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxy-cyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II. Cancer Res 1992, 52, 3515-3520.
11. 11. Calabresi P, Parks RE Jr. Antiproliferative agents and drugs used for immunosuppression. In Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics. New York, MacMillan, 1985, 1283-1285.
12. 12. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994, 47, 223-258.
13. 13. Kimura K, Saijo M, Ui M, Enomoto T. Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 1994, 269, 1173-1176.
14. 14. Toffoli G, Viel A, Tumiotto L, Biscontin G, Rossi C, Boiocchi M. Pleiotropic-resistance phenotype in a multifactorial phenomenon in human colon carcinoma cell lines. Br J Cancer 1991, 63, 51-56.
15. 15. Tarasiuk J, Foucrier J, Garnier-Suillerot A. Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells. Biochem Pharmacol 1993, 45, 1801-1808.
16. 16. Lee WP. The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. Cancer Lett 1993, 73, 105-111.
17. 17. Erba E, Sen S, Lorico A, D'Incalci M. Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur J Cancer 1992, 28, 66-71.
18. 18. Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi M. Expression of the mdr1 gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines. Cancer Chemother Pharmacol 1992, 29, 283-289.
19. 19. Toffoli G, Simone F, Gigante M, Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem Pharmacol 1994, 48, 1871-1881.